- Transmission/Exposure Routes
- Case Fatality Ratio
- Incubation periods
- Burden of Disease
- Environmental Survival
- Recommended Dose Response Model
Animal and human
Infection of humans usually occurs by inhalation of these organisms from air that contains airborne barnyard dust contaminated by dried placental material, birth fluids, and excreta of infected animals
The estimated case fatality rate is low, at 1-2% of hospitalized patients.
The acute symptoms usually develop within 2-3 weeks of exposure, although as many as half of humans infected do not show symptoms
Q Fever became a reportable disease in the United States in 1999. Between 2000 and 2004, the US saw an average of 51 cases every year. In 2005, 136 cases were reported to the CDC, and 169 in 2006.
The annual has been reported as 0.28 cases per million persons
Internationally, prevelance is estimated from 5% in urban areas to 30% in rural areas. This is likely an underestimate due to asymptomatic infections. Results of serological testing of blood donors revealed a prevalence of 18% to 37% in Africa. The United Kingdom sees approximately 100 cases of Q Fever a year
Duration of infectiousness and disease
Q fever is rarely contagious between humans.
Acute illness responds well to antibiotic treatment, and fevers usually resolve in an average of 4.3 days
Chronic illness is less common, but can develop if an acute illness is not treated quickly. Endocartitis accounts for 60-70% of chronic Q fever and is the most common cause of fatality of the illness.
Most patients (50-60%) infected with Q fever are asymptomatic. Those who do show symptoms present flu-like symptoms including fevers, coughs, sweats, myalgias, and arthralgias. Other possible symptoms are pneumonia and hepatitis.
Excretion Rates (see Exposure)
Live, whole-cell, and acellular vaccines have been developed for Q fever.
Obligate intracellular small Gram-negative bacteria
The organism is extremely hardy and resistant to heat, drying, and many common disinfectants which enable the bacteria to survive for long periods in the environment
Coxiella burnetii: Dose Response Models
Beta-Poisson: α is 0.36, N50 is 4.93E+08
- Parker, N. R., Barralet, J. H., & Bell, A. M. (25 February). Q fever. The Lancet, 367(9511), 679–688. doi:10.1016/S0140-6736(06)68266-4 [Http//:www.sciencedirect.com/science/article/pii/S0140673606682664 Full Text]
- CDC Page
- McQUISTON, J. H., Holman, R. C., McCALL, C. L., Childs, J. E., Swerdlow, D. L., & Thompson, H. A. (2006). National Surveillance and the Epidemiology of Human Q Fever in the United States, 1978–2004. The American Journal of Tropical Medicine and Hygiene, 75(1), 36–40. Full Text
- Struble, K. Cunha, B. (2012) "Q Fever" Medscape Reference. http://emedicine.medscape.com/article/227156-overview#a0156
- Hartzell, J. D., Wood-Morris, R. N., Martinez, L. J., & Trotta, R. F. (2008). Q Fever: Epidemiology, Diagnosis, and Treatment. Mayo Clinic Proceedings, 83(5), 574–579. doi:10.4065/83.5.574 Full Text